A 2026 review examined cannabichromene (CBC), a naturally occurring, non-intoxicating cannabinoid found in Cannabis sativa. Although CBC is considered one of the more abundant phytocannabinoids in many cannabis varieties, it has received far less research attention than THC, CBD, and CBG. The review explored how CBC is produced in the plant, how it is absorbed and metabolized in the body, and how it interacts with biological targets, including transient receptor potential (TRP) channels.

Preclinical studies reviewed by the authors suggest that CBC may have anti-inflammatory, pain-relieving, antimicrobial, anticancer, neuroprotective, antidepressant, and dermatological properties. CBC appears to act differently from THC, with minimal direct activity at the CB1 and CB2 cannabinoid receptors, which may contribute to its lack of intoxicating effects. Researchers are also interested in how CBC may work alongside other cannabinoids and plant compounds as part of the proposed “entourage effect.”

Despite its potential, CBC remains understudied, and the authors emphasize that there are currently no clinical trials establishing its effectiveness as a treatment in humans. Challenges including low oral bioavailability, possible drug interactions, formulation limitations, and an evolving regulatory landscape will need to be addressed. The review concludes that CBC is a promising cannabinoid for further preclinical and clinical research, particularly as scientists work to better understand its safety, dosing, and therapeutic applications.

Source: Elbouzidi A, Baraich A, Haddou M, et al. Cannabichromene (CBC): a comprehensive review of biosynthesis, pharmacology, therapeutic potential, and translational perspectives. Journal of Cannabis Research. 2026. DOI: 10.1186/s42238-026-00454-4. PMID: 42464425. https://pubmed.ncbi.nlm.nih.gov/42464425/